Cardiovascular Drugs Market By Disease Type (Hypertension, Congestive Heart disease, Angina pectoris, Myocardial Ischemia, Peripheral Artery Diseases, Atherosclerosis, Cardiomyopathy, Others), By Drug Class (Anti-hypertensive Drugs, Lipid lowering drugs, Beta-adrenergic Blocking Agents, Vasodilators, Anti-platelet Agents, Others), By Route of Administration (Oral, Buccal/sublingual, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

 

Cardiovascular Drugs Market size was valued at USD 146.51 billion in 2021, at a CAGR of 4.8% during the forecast period 2021-2027. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has tremendous growth rate over the forecast years owing to increase in the prevalence of various cardiovascular diseases and rise in R&D activities for the innovation of newer drugs. According to World Health Organization 2015, approximately 17.7 Mn deaths occured due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for the R&D activities, and patent expiration of blockbuster are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of cardiovascular drugs market. Key Developments: In November 2015, AstraZeneca acquired ZS Pharma to strengthen its cardiovascular drugs portfolio by developing novel treatment for hyperkalemia, typically associated with chronic heart failure (CHF). In June 2016, Espero Pharmaceuticals received FDA approval for Gonitro (Nitroglycerin) sublingual powder used for acute relief of an angina pectoris attack due to coronary artery disease.